Modern biotechnology Dr Nataporn Chanvarasuth

Technical Session VPolicy and Institutional Frameworks for Hi-tech Innovation Systems

Modern biotechnology

Year 2030 Bioeconomy

OECD: The bioeconomy in 2030 is likely to involve three elements: 1. advanced knowledge of genes and complex cell processes2. renewable biomass3. integration of biotechnology applications across sectors.

OECD = the Organization for Economic Co-operation and Development

Bioeconomy: Born from necessity : Need innovation to meet the challenges

Energy crisis

Climate change &Resource crisis

Emerging diseases Well being & Aging people

pollution

Biotechnology: the fourth wave to solve the global problems

Green products

Green process

Plants: high production + resistant traitsBioremediation

Diagnostic deviceMedical systemVaccine

NutraceuticalFunctional food

Specific Characteristics of Biotech Business

• Knowledge based industry

• Diverse benefit

• High investment and long-term return (~3-10 years)

• SMEs (Size < 100 employees)

• High control & regulation

• Market oriented

http://www.slideshare.net/danielsatinsky/boston-innovation-ecosystem-st-petersburg

Heart of innovation ecosystem is the regular and constant interaction bringing great science with entrepreneurs

To help reduce some risks, government needs to provide suitable supports: Innovation ecosystem

http://www.biowin.org/biowin/en/5408-home.html

To create innovation ecosystem, Wallonia region identify 6 competitive clustersStrategy of the BioWin cluster (health cluster)

BioWin is a not-for-profit organization. This unit is governed by a governing board, assisted by a permanent operational team.

BioWin gathers more than500 members:• 130 companies (125 SMEs and 5 Global leaders: Baxter, GSK, IBA, UCB, and Eurogentec-Kaneka • 400 research centers, 5 universities

2x2 model for innovation

Open Innovation• Key elements: networking, collaboration with partners, competitors, universities, and users • proactive intellectual property management• R&D to obtain competitive advantage

“Partners with others to create the most and the best ideas in the industry”

“ Make profit from the other’s use of our IP, and also buy others’ IP when it advances our business model”

Specify future niche direction from own strength and alsoNation’s master plan

USA - medical innovation focusing human health- food & agriculture- biobased industry using industrial enzyme

Japan- medical technology- in vitro diagnostics- drug discovery- medical device, functional food

Taiwan - Hub of clinical trial in Asia- focus on traditional Chinese herbal medicines

Process to identify niche direction1. Select innovation/capability focus2. Uncover customer needs3. Priority customer needs4. Develop strategy

Provide suitable environment … vision with commitment

USA- provide tax incentives for SMEs - support source of money (venture capital funding)

Malaysia- Create Bill of Guarantees for biotech companies to ensure IP protection and freedom to import capital and labor- Create BiotechCorp as a convenient one-stop shop for biotech companies providing funding and assistance with IP, immigration, regulation, and employment matters- Launched the Biotechnology Commercialization Fund

Singapore- Commercialization framework via Exploit Technologies (business arm of A*STAR) bridging R&D to industry- government incentives ex. Match $ per $- world-class R&D infrastructure

Suitable environment• budget• infrastructure• host • etc.

Set up systems to expedite technology transfer and commercialization

Soft services to serve researchers and startups• IP protection• incubation: coaching & mentoring• commercialize process & marketing

https://www.bio.org/sites/default/files/GPP-FINAL-2-1-2013.pdf

Provide a transparent and predictable regulatory approval process

Singapore- Integration among govt. and private agencies: : Biomedical Research council: Singapore Economic Development Board (EDB): Biomedical Science Group: Ministry of Health (MOH),and Bio*One Capital: A*STAR Joint Council to support interdisciplinary researchTaiwan

- Multiministerial efforts supervised by Science and Technology Advisory Group of the Executive Yuan (Cabinet): National Science Council + the Ministry of Economic Affairs

Maintain transparent, non-discriminatory, competitive, and commercially viable market for biotech productsUSA launches BioPreferred program to certify

biobased products (government procurement)

• managed by the US Department of Agriculture (USDA) • to increase the purchase and use of bio-based products • 2 major parts of the program: - mandatory purchasing requirements for federal agencies and their contractors - voluntary labeling initiative for bio-based products

Thai Government Policy to support STI

Increase R&D investment to 1% of GDPRatio of public and private = 30:70

Support Maga projectsUse Thai innovation for government procurement

Create innovation society - STEM education- talent mobility

Improve law & regulation to push R&D for commercialization

Develop infrastructure for science, technology, and innovation

http://unctad.org/meetings/en/Presentation/ecn162015p15_Durongkaveroj_en.pdf

http://unctad.org/meetings/en/Presentation/ecn162015p15_Durongkaveroj_en.pdf

Area: 80 AcresSpace: 140,000 m2

Types of space: Incubator units, wet/dry labs, long-term leased land

At present: 60 companies, 20 incubatees

Thailand Science ParkThailand Science Park

Infrastructure for Knowledge Business

Convention CenterMulti-tenant Incubator

BuildingGreenhouse

Pilot PlantNational Centers

Thailand Science Park - Phase 2

• Four integrated towers• Gross area of around 127,000 sq.m., Net area of 72,000 sq.m.• 40,000 sq.m. allocated for private companies• Clean room, sensitive lab, heavy equipment areas available

NSTDA: Linkage between R&D and Business

Infrastructure & Facility

NSTDA’s soft services

http://unctad.org/meetings/en/Presentation/ecn162015p15_Durongkaveroj_en.pdf

AYUBOVON

KHOB KHUN KHA